Moran Frenkel-Pinter

Postdoctoral Fellow
Georgia Institute of Technology, IBB 2203

B.S., Tel Aviv University, 2009 M.S., Tel Aviv University, 2012 Ph.D., Tel Aviv University, 2016

Research Interests: 

Chemical Mutualism, Origins of Life, Protopeptide Self-Assembly, As a NASA postdoctoral fellow in the Center for the Origin Of Life and the Center for Chemical Evolution, my research focuses on elucidating mechanisms that lead to the formation of proto-peptides that can spontaneously polymerize, fold and function under prebiotic conditions.

Selected publications: 

Shaltiel-Karyo R¥, Frenkel-Pinter M¥, Rockenstein E, Patrick C, Egoz-Matia N, Masliah E, Segal D and Gazit E. A BBB disrupter is also a potent α-synuclein aggregation inhibitor: A novel dual mechanism of mannitol for the treatment of Parkinson’s disease. J Biol Chem.2013, 288(24):17579-88. ¥ contributed equally to this work

Frenkel-Pinter M, Richman M, Belostozky A, Abu-Mokh A, Gazit E, Rahimipour S and Segal D. Selective inhibition of aggregation of amyloidogenic Tau-derived peptide using its glycosylated analogs. Chemistry. 2016; 22(17):5945-52.

Frenkel-Pinter M, Tal S, Scherzer-Attali R, Abu-Hussien M, Alyagor I, Eisenbaum T, Gazit E and Segal D. Cl-NQTrp alleviates tauopathy symptoms in a model organism through inhibition of tau aggregation-engendered toxicity. Neurodegener Dis. 2017; 17(2-3):73-82.

Frenkel-Pinter M, Stempler S, Tal S, Waldman Y, Losev L, Ruppin E, Gazit E and Segal D. Altered protein glycosylation predicts Alzheimer's disease and modulates its pathology in disease model Drosophila. Neurobiol Aging. 2017; 56:159-171. 

Frenkel-Pinter M, Shmueli M, Raz C, Yanku M, Gazit E and Segal D. Interplay between protein glycosylation pathways in Alzheimer's disease. Sci Adv. 2017; 3(9).